142 related articles for article (PubMed ID: 36400733)
1. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with
Hegi-Johnson F; Rudd SE; Wichmann C; Akhurst T; Roselt P; Trinh J; John T; Devereux L; Donnelly PS; Hicks R; Scott AM; Steinfort D; Fox S; Blyth B; Parakh S; Hanna GG; Callahan J; Burbury K; MacManus M
BMJ Open; 2022 Nov; 12(11):e056708. PubMed ID: 36400733
[TBL] [Abstract][Full Text] [Related]
2. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET.
Pouw JEE; Hashemi SMS; Huisman MC; Wijngaarden JE; Slebe M; Oprea-Lager DE; Zwezerijnen GJC; Vugts D; Ulas EB; de Gruijl TD; Radonic T; Senan S; Menke-van der Houven van Oordt CW; Bahce I
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302416
[TBL] [Abstract][Full Text] [Related]
3.
Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
[TBL] [Abstract][Full Text] [Related]
5.
Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
[TBL] [Abstract][Full Text] [Related]
6. Automated radiosynthesis of [
Wichmann CW; Poniger S; Guo N; Roselt P; Rudd SE; Donnelly PS; Blyth B; Van Zuylekom J; Rigopoulos A; Burvenich IJG; Morandeau L; Mohamed S; Nowak AK; Hegi-Johnson F; MacManus M; Scott AM
Nucl Med Biol; 2023; 120-121():108351. PubMed ID: 37224789
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive evaluation of PD-L1 expression in non-small cell lung cancer by immunoPET imaging using an acylating agent-modified antibody fragment.
Cheng Y; Shi D; Ye R; Fu W; Ma P; Si Z; Xu Z; Li L; Lin Q; Cheng D
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1585-1596. PubMed ID: 36759371
[TBL] [Abstract][Full Text] [Related]
9. Imaging diagnosis and efficacy monitoring by [
He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
[No Abstract] [Full Text] [Related]
10. Study of
Niemeijer AN; Oprea-Lager DE; Huisman MC; Hoekstra OS; Boellaard R; de Wit-van der Veen BJ; Bahce I; Vugts DJ; van Dongen GAMS; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 Mar; 63(3):362-367. PubMed ID: 34272316
[TBL] [Abstract][Full Text] [Related]
11. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
[TBL] [Abstract][Full Text] [Related]
12. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of
Farwell MD; Gamache RF; Babazada H; Hellmann MD; Harding JJ; Korn R; Mascioni A; Le W; Wilson I; Gordon MS; Wu AM; Ulaner GA; Wolchok JD; Postow MA; Pandit-Taskar N
J Nucl Med; 2022 May; 63(5):720-726. PubMed ID: 34413145
[TBL] [Abstract][Full Text] [Related]
13.
Al-Zubaidi M; Viswambaram P; McCombie S; Liow E; Lenzo N; Ferguson T; Redfern AD; Gauci R; Hayne D
BMJ Open; 2022 Apr; 12(4):e060478. PubMed ID: 35428649
[TBL] [Abstract][Full Text] [Related]
14. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
Shirasawa M; Yoshida T; Imabayashi T; Okuma K; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Tsuchida T; Yamamoto N; Nakayama Y; Watanabe SI; Motoi N; Ohe Y
Eur J Cancer; 2022 Feb; 162():1-10. PubMed ID: 34936940
[TBL] [Abstract][Full Text] [Related]
15. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
[TBL] [Abstract][Full Text] [Related]
16. Preclinical development of novel PD-L1 tracers and first-in-human study of [
Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
[TBL] [Abstract][Full Text] [Related]
17. Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer.
Bucknell N; Hardcastle N; Jackson P; Hofman M; Callahan J; Eu P; Iravani A; Lawrence R; Martin O; Bressel M; Woon B; Blyth B; MacManus M; Byrne K; Steinfort D; Kron T; Hanna G; Ball D; Siva S
BMJ Open; 2020 Dec; 10(12):e042465. PubMed ID: 33303468
[TBL] [Abstract][Full Text] [Related]
18. Phase I study to assess safety, biodistribution and radiation dosimetry for
Merkx RIJ; Lobeek D; Konijnenberg M; Jiménez-Franco LD; Kluge A; Oosterwijk E; Mulders PFA; Rijpkema M
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3277-3285. PubMed ID: 33651116
[TBL] [Abstract][Full Text] [Related]
19. A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma.
Lin C; Ballah T; Nottage M; Hay K; Chua B; Kenny L; Thomas P; Teng M; Keller J; Le T; Edmunds J; Hughes B
Radiat Oncol; 2021 Apr; 16(1):69. PubMed ID: 33836800
[TBL] [Abstract][Full Text] [Related]
20. Imaging PD-L1 Expression with ImmunoPET.
Truillet C; Oh HLJ; Yeo SP; Lee CY; Huynh LT; Wei J; Parker MFL; Blakely C; Sevillano N; Wang YH; Shen YS; Olivas V; Jami KM; Moroz A; Jego B; Jaumain E; Fong L; Craik CS; Chang AJ; Bivona TG; Wang CI; Evans MJ
Bioconjug Chem; 2018 Jan; 29(1):96-103. PubMed ID: 29125731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]